caa a22 4500 605490740 CHVBK 20210128100506.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s10147-015-0829-0 doi (NATIONALLICENCE)springer-10.1007/s10147-015-0829-0 Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status [Elektronische Daten] [Yoshihiro Nishida, Satoshi Tsukushi, Hiroshi Urakawa, Shunsuke Hamada, Eiji Kozawa, Kunihiro Ikuta, Yuichi Ando, Naoki Ishiguro] Background: This study was conducted to determine the efficacy and safety of low-dose chemotherapy with methotrexate (MTX) and vinblastine (VBL) for patients with desmoid tumors refractory to meloxicam treatment, focusing in particular on the relationship between the efficacy of this chemotherapy and catenin β-1 (CTNNB1) mutation status. Patients and methods: Since March 2003, patients pathologically diagnosed with extraperitoneal desmoid tumors have been prospectively treated with meloxicam, a COX-2 inhibitor, at our institution. Patients with inoperable tumors who were resistant to meloxicam treatment underwent MTX and VBL therapy every other week. The responses of all patients were evaluated, and factors that were correlated with efficacy were analyzed, including CTNNB1 mutation status. Results: Sixty-eight patients were prospectively treated with meloxicam. MTX+VBL therapy was administered in 15 patients. Six patients showed a partial response. Only one patient presented disease progression. A few patients showed grade 3-4 treatment-related toxicity with the administration of MTX and VBL every other week. Intriguingly, CTNNB1 status did not affect the efficacy of this treatment. Conclusion: MTX and VBL treatment every other week is well tolerated and achieved a favorable response in patients resistant to meloxicam treatment, regardless of CTNNB1 mutation status. Japan Society of Clinical Oncology, 2015 Desmoid tumor nationallicence CTNNB1 nationallicence Methotrexate nationallicence Vinblastine nationallicence Nishida Yoshihiro Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut Tsukushi Satoshi Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut Urakawa Hiroshi Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut Hamada Shunsuke Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut Kozawa Eiji Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut Ikuta Kunihiro Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut Ando Yuichi Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Japan aut Ishiguro Naoki Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut International Journal of Clinical Oncology Springer Japan 20/6(2015-12-01), 1211-1217 1341-9625 20:6<1211 2015 20 10147 https://doi.org/10.1007/s10147-015-0829-0 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0829-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Nishida Yoshihiro Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut NATIONALLICENCE 700 1- Tsukushi Satoshi Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut NATIONALLICENCE 700 1- Urakawa Hiroshi Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut NATIONALLICENCE 700 1- Hamada Shunsuke Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut NATIONALLICENCE 700 1- Kozawa Eiji Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut NATIONALLICENCE 700 1- Ikuta Kunihiro Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut NATIONALLICENCE 700 1- Ando Yuichi Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Japan aut NATIONALLICENCE 700 1- Ishiguro Naoki Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, 466-8550, Nagoya, Aichi, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/6(2015-12-01), 1211-1217 1341-9625 20:6<1211 2015 20 10147